The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer
Year: 2020
Type: article
Study design: Observational Study
Abstract: Accumulating evidence suggests that dysregulation of transcriptional enhancers plays a significant role in cancer pathogenesis. Herein, we performed a genome-wide discovery of enhancer elements in colorectal cancer (CRC). We identified PVT1 locus as a previously unrecognized transcriptional regulator in CRC with a significantly high enhancer activity, which ultimately was responsible for regulating the expression of MYC oncogene. High expression of the PVT1 long-non-coding RNA (lncRNA) transcribed from the PVT1 locus was associated with poor survival among patients with stage II and III CRCs (p < 0.05). Aberrant methylation of the PVT1 locus inversely correlated with the reduced expression of the corresponding the PVT1 lncRNA, as well as MYC gene expression. Bioinformatic analyses of CRC-transcriptomes revealed that the PVT1 locus may also broadly impact the expression and function of other key genes within two key CRC-associated signaling pathways - the TGFβ/SMAD and Wnt/β-Catenin pathways. We conclude that the PVT1 is a novel oncogenic enhancer of MYC and its activity is controlled through epigenetic regulation mediated through aberrant methylation in CRC. Our findings also suggest that the PVT1 lncRNA expression is a promising prognostic biomarker and a potential therapeutic target in CRC.
Source: Molecular Cancer
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,290
Awards: G1081931513, G1285155450, G2242390953, G2406107095, G312429407, G3173870227, Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer, G3411000325, G3484629817, G4144402113, G4300560175, Exploration of the Molecular Biological Characteristics of Advanced Colorectal Cancer Suitable for Sequential Therapy, G6681643532, G7086259105, G7495828879, Preemptive Medicine to Solid Tumors based on Epigenomics, Integrators of Metastatic Potential, Specialized Cancer Center Support Grant, G791104374, Construction of innovative preemptive medicine for gastrointestinal cancer especially including pancreatic cancer, G8436895423, Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population Data, Methylation Biomarker Development for Noninvasive Detection of Colorectal Cancer
OpenAlex ID: W3096002368
